

The role of leukocytes in thrombosis

Laura L. Swystun¹ and Patricia C. Liaw²

¹Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada, and ²Thrombosis and Atherosclerosis Research Institute and Department of Medicine, McMaster University, Hamilton, ON, Canada

In recent years, the traditional view of the hemostatic system as being regulated by a coagulation factor cascade coupled with platelet activation has been increasingly challenged by new evidence that activation of the immune system strongly influences blood coagulation and pathological thrombus formation. Leukocytes can be induced to express tissue factor and release proinflammatory and procoagulant molecules such as granular enzymes, cytokines, and damage-associated

molecular patterns. These mediators can influence all aspects of thrombus formation, including platelet activation and adhesion, and activation of the intrinsic and extrinsic coagulation pathways. Leukocyte-released procoagulant mediators increase systemic thrombogenicity, and leukocytes are actively recruited to the site of thrombus formation through interactions with platelets and endothelial cell adhesion molecules. Additionally, phagocytic leukocytes are involved in

fibrinolysis and thrombus resolution, and can regulate clearance of platelets and coagulation factors. Dysregulated activation of leukocyte innate immune functions thus plays a role in pathological thrombus formation. Modulation of the interactions between leukocytes or leukocyte-derived procoagulant materials and the traditional hemostatic system is an attractive target for the development of novel antithrombotic strategies. (Blood. 2016;128(6):753-762)

Introduction

Hemostatic thrombus formation is conventionally thought to involve a coagulation factor cascade coupled with platelet activation. Pathological thrombosis, as described in the 1850s by the German pathologist Rudolph Virchow, is influenced by aberrant activation of coagulation, disruption of the vessel wall, and stasis.¹ However, in recent years this model has undergone a significant paradigm shift due to accumulating evidence of an intrinsic link between the coagulation and innate inflammatory systems. The term immunothrombosis, coined in 2013 by Engelmann and Massberg,² formalized this concept and described a process by which the activation of coagulation assists the function of the innate immune system, and the converse, whereby components of the immune system contribute to thrombosis. Dysregulated activation of the immune system can thus contribute to the genesis of pathological macro- and microvascular thrombosis.

The contribution of leukocytes to coagulation is a subject of both longstanding interest as well as current intensive study. With the development of intravital imaging techniques, animal models that closely mimic the pathogenesis of thrombosis in humans, and selective antagonists of leukocyte-regulated procoagulant pathways, the role that leukocytes play in regulating thrombosis is being unveiled. Leukocytes, namely monocytes, macrophages, and neutrophils, express and release coagulation and fibrinolytic factors, and interact with the hemostatic system through innate immune functions. Leukocytes produce cytokines that modulate the expression of procoagulant and adhesive molecules on vascular endothelial cells. Antimicrobial agents released during leukocyte degranulation and extracellular trap formation directly activate platelets and the coagulation cascade. Additionally, leukocyte chemotaxis and phagocytic functions regulate thrombus resolution. In this review, the influence of leukocytes on blood coagulation and platelet activation will be described, and evidence assessing the contribution of leukocytes to venous, arterial, and microvascular thrombosis will be considered.

Leukocytes regulate the coagulation cascade

Under normal physiological circumstances, quiescent leukocytes promote the maintenance of blood fluidity. For example, circulating monocytes express the anticoagulant factors endothelial protein C receptor (EPCR),³ thrombomodulin (TM),⁴ and tissue factor pathway inhibitor (TFPI).⁵ However, under proinflammatory or apoptotic conditions, leukocytes can rapidly undergo a phenotypic transformation, synthesizing and secreting procoagulant factors or agents that activate coagulation (Figure 1). Additionally, the leukocyte cell surface can provide a site for coagulation factor assembly and activation.^{6,7}

Tissue factor (TF)

Monocytes are the largest intravascular source of TF.^{8,9} Although low levels of TF antigen are detected on quiescent monocytes, exposure to agents that promote inflammation, and/or apoptosis, including high mobility group box-1 (HMGB-1),¹⁰ chemotherapy,¹¹ lipopolysaccharide,¹² hypoxia,¹³ and anti-HIT antibodies¹⁴ increase monocyte TF activity and/or TF-mediated thrombin generation. Monocyte TF activity is regulated by processes that increase TF expression, induce TF decryption,¹⁵ and modulate the balance between TF and TFPI.¹⁶ Activated monocytes also shed microparticles from P-selectin glycoprotein ligand 1 (PSGL-1)-rich membrane microdomains¹⁷ that carry TF, phosphatidylserine, and other regulators of coagulation.¹⁸ Expression of TF by other leukocyte subtypes is more controversial. Although quiescent neutrophils likely do not express TF antigen,¹⁹ TF can be expressed in smaller quantities by neutrophils stimulated *ex vivo*^{20,21} and in animal models.^{22,23} This may in part be the result of neutrophil acquisition of TF from monocytes,²⁴ potentially through a process involving microparticle-mediated transfer. Similarly,




Figure 1. Leukocyte-released enzymes and DAMPs interact with components of the coagulation cascade. CF-DNA, histones, MMP, cathepsin G, and/or elastase modulate the traditional coagulation cascade by facilitating the activation of zymogen coagulation and fibrinolytic factors, and inhibiting the activity of endogenous anticoagulants. TF expressed by circulating leukocytes can activate coagulation through the extrinsic pathway, whereas monocyte-derived uPA can modulate fibrinolysis. CF-DNA, cell-free DNA; MMP, matrix metalloproteinase; PAI, plasminogen activator inhibitor; uPA, urokinase-type plasminogen activator.

conflicting reports describe the expression of TF by eosinophils, but may partially explain the increased risk for thrombosis in eosinophilia.²⁵⁻²⁷

Granular enzymes

Neutrophils, and to a lesser extent monocytes, and basophils release matrix metalloproteinases and serine proteases such as cathepsin G and elastase, from cytoplasmic granules in response to stimulation.^{28,29} These enzymes promote coagulation activation through numerous mechanisms (Figure 1), including directly activating cofactors factor V (FV),³⁰ FVIII,³¹ and zymogen FX.³² They can also degrade anticoagulant factors such as antithrombin,³³ heparin cofactor II,³⁴ and/or TFPI.³⁵⁻³⁷

Nuclear damage-associated molecular patterns (DAMPs)

DAMPs, including DNA, HMGB1, and histones are released from the nuclei of activated or apoptotic leukocytes and promote the activation of coagulation. The release of neutrophil chromatin as neutrophil extracellular traps (NETs) can be triggered by exposure to microorganisms, activated platelets, inflammatory cytokines, and HMGB1.³⁸⁻⁴¹ As well, NETs have also been reported to be released by monocytes/macrophages⁴² and mast cells,⁴³ whereas basophils⁴⁴ and eosinophils⁴⁵ release extracellular traps comprised of granular enzymes and mitochondrial DNA. CF-DNA may also be released from apoptotic or necrotic cells in the circulation or vessel wall.⁴⁶

Intact NETs act as a scaffold that concentrates procoagulant effectors including platelets, red blood cells, von Willebrand factor (VWF), TF, protein disulfide isomerase, HMGB1, cathepsin G, elastase, fibrin (ogen), and fibronectin.^{22,47,48} The influence of NET components on coagulation activation has been independently evaluated (Figure 1). Extracellular DNA triggers contact pathway activation through FXI and FXII.^{49,50} Histone H4 binds to prothrombin and generates thrombin by auto-activation.⁵¹ DAMPs can also inhibit anticoagulant pathways by protecting thrombin from antithrombin-mediated inactivation,^{52,53} and by impairing protein C activation by thrombin-TM.^{10,54}

Leukocytes modulate the hemostatic activity of endothelial cells and platelets

Leukocyte-released antimicrobial enzymes, cytokines, and DAMPs, can modulate the anticoagulant activity of endothelial cells (Figure 2). Cytokines such as tumor necrosis factor- α and interleukin-1 β can downregulate expression of EPCR and TM through decreased messenger RNA synthesis,⁵⁵ and increased EPCR shedding.⁵⁶ Histones are cytotoxic to endothelial cells,⁵⁷ and increase surface phosphatidylserine exposure on erythrocytes.⁵⁸ Histones,⁵⁹ cytokines,⁶⁰ HMGB1,¹⁰ and granular enzymes⁶¹ can increase in vitro endothelial cell TF activity. Histones and cytokines can also stimulate the exocytosis of endothelial Weibel-Palade bodies, inducing the release of VWF and/or P-selectin.^{62,63} Activated basophils also release histamine,²⁹ a potent secretagogue for VWF.⁶⁴ Additionally, both cytokines and neutrophil-generated oxidants such as HOCl impair cleavage of VWF by the protease ADAMTS13, potentially increasing the proportion of circulating ultralarge VWF multimers with enhanced platelet-binding abilities.^{63,65}


Although activated platelets can stimulate NETosis,⁴¹ leukocytes interact with activated platelets to form heterotypic leukocyte-platelet aggregates (Figure 3B). Exposure to proinflammatory and procoagulant stimuli, as well as high shear stress have been shown to promote the formation of these complexes.⁶⁶⁻⁶⁹ Heterotypic aggregates form when activated, and degranulated platelets expose P-selectin on their surface that binds to leukocyte surface PSGL-1.⁷⁰ Signaling through PSGL-1 rapidly upregulates leukocyte expression of α M β 2⁷¹ that binds platelet GPIIb/IIIa⁷² or GPIIb/IIIa via a fibrinogen intermediate (Figure 3B).⁷³ The complexes are further stabilized by multiple receptor-ligand interactions including CD40-CD40 ligand,⁷⁴ extracellular matrix metalloproteinase inducer-glycoprotein VI (GPVI),⁷⁵ lymphocyte function-associated antigen 1-ICAM-2,⁷⁶ and junctional adhesion molecule-C- α M β 2.⁷⁷ PSGL-1 engagement can also activate cooperative signaling through NF- κ B to induce the production of proinflammatory cytokines.⁷⁸ Although conflicting reports exist, evidence suggests that platelet P-selectin interactions with leukocyte PSGL-1 may also activate TF on monocytes and/or neutrophils.^{20,78,79} Increased levels of leukocyte-platelet aggregates are frequently associated with thromboinflammatory disorders, and can be used as stable markers of underlying hypercoagulability.

Activated leukocytes can also induce platelet activation and aggregation by releasing potent platelet activators including elastase,⁸⁰ cathepsin G,⁸¹ and platelet activating factor (Figure 2).⁸² The influence of NETs on platelet activation has been characterized using several in vitro and in vivo models. NETs can bind to both platelets and VWF under shear,⁴⁷ and stimulation of endothelial cells by histones increases platelet capture by VWF in a flow chamber system.⁶² This interaction is likely mediated by both increased Weibel-Palade body exocytosis and platelet activation, as both intact NETs⁵⁰ and extracellular histones induce platelet activation via toll-like receptor 2 (TLR2) and TLR4.^{83,84} Platelet activation by histones promote the formation of leukocyte-platelet aggregates and induces the release of platelet VWF, P-selectin, and polyphosphate, which promotes platelet-dependent thrombin generation.^{69,84} In vivo, infusions of extracellular histones promote the formation of platelet-rich microthrombi with concomitant thrombocytopenia.⁸³

Leukocytes contribute to deep vein thrombosis (DVT)

Clinical studies have described evidence of activated leukocytes associated with venous, arterial, and microvascular thrombosis. Elevated

Figure 2. Leukocyte-released enzymes, DAMPs, and cytokines regulate the hemostatic activity of endothelial cells and platelets. Mediators released by activated leukocytes can influence the hemostatic activity of the endothelium and platelet activation. WPB, Weibel-Palade body.



levels of circulating markers of NETs and neutrophil activation,^{85,86} as well as increased monocyte TF,^{87,88} have been observed in patients with DVTs compared with control subjects. In addition to releasing disseminated procoagulant factors into the blood, it is increasingly recognized that leukocytes also assemble at the site of vascular injury, and are actively incorporated into forming thrombi. Studies evaluating the composition of venous thrombi from humans demonstrated the presence of TF-expressing leukocytes and NETs.^{89,90} These processes increase the localized concentration of leukocyte-derived procoagulant activity and potentially forms the nidus upon which the thrombus develops.

Experimental animal models have also shown the association of leukocyte recruitment with the induction of venous thrombosis. In the detailed characterization of a mouse inferior vena cava (IVC) stenosis model, the recruitment of leukocytes to the site of venous thrombosis occurred overlying the intact but activated endothelium within an hour of vessel flow restriction.²² Within 6 hours, leukocytes overlay the endothelial surface, with neutrophils and monocytes comprising 70% and 30% of leukocytes within the thrombus, respectively. Leukocyte recruitment may also be facilitated by the release of cytokines and chemokines by activated platelets,⁹¹ which bind directly to the endothelium, or form heterotypic aggregates within the venous thrombus.^{22,92} Leukocyte rolling is mediated by the upregulation of selectins on the endothelial surface that binds leukocyte PSGL-1, and genetic deletion of P- and E-selectins reduces leukocyte accumulation and venous thrombus size (Figure 3A).^{22,93} Firm attachment of leukocytes can involve endothelial VWF, VCAM, and ICAM binding leukocyte PSGL-1 and integrins.^{22,94-96}

Assessment of the contribution of leukocytes to the genesis of venous thrombosis is dependent on the animal model used. Both neutrophil and monocyte depletion inhibit thrombosis in murine IVC stenosis²² and ferric chloride models,⁹⁷ respectively. With respect to leukocyte TF, infusion of activated TF-expressing monocytes resulted in systemic venous and arterial thrombosis in rabbits,⁹⁸ and IVC ligation models have demonstrated the presence of TF-expressing leukocytes within venous thrombi in rabbits⁹⁹ and rats.¹⁰⁰ In the venous stenosis IVC ligation model, selective depletion of hematopoietic TF significantly attenuates thrombus formation²²; however, in contrast,

DVT formation in response to complete IVC stasis does not involve hematopoietic TF.¹⁰¹

Although the majority of leukocyte-released TF associated with venous thrombi is likely derived from monocytes, neutrophils have also been variably implicated in the formation of DVT. For example, NETs are associated with venous thrombi derived from murine and baboon models.^{102,103} Infusions of extracellular histones promote DVT development in murine IVC stenosis models, whereas the administration of DNase1, or FXII deficiency attenuates DVT formation.^{22,103} In contrast, a model of spontaneous venous thrombosis using small interfering RNA knockdown of protein C and antithrombin, showed that although neutrophils were associated with venous thrombi, neutrophil depletion did not diminish thrombus formation.¹⁰⁴ Interestingly, protein arginine deiminase 4 (PAD4) and neutrophil elastase, which regulate chromatin decondensation and NETosis, have contradictory influence on DVT induction. Although PAD4 deficiency was associated with impaired thrombus formation in the IVC stenosis model,¹⁰⁵ an electrolytic injury model reported no influence of PAD4 deficiency on DVT.¹⁰⁶ Additionally, neutrophil elastase deficiency has been shown to impair NET formation in response to microbial infection,^{107,108} however, a sterile IVC stenosis model demonstrated elastase-deficient mice generate NETs and have normal venous thrombi.¹⁰⁹ Although overall these studies appear to support a role for leukocytes in the induction of thrombosis in response to venous stenosis, they also highlight how the variability of the models employed, including the extent of endothelial injury and underlying activation status of circulating leukocytes, can influence the induction of venous thrombosis.

Leukocytes contribute to arterial thrombosis

Leukocytes can participate in atherothrombosis by generating procoagulant material within the atherosclerotic plaque and contributing to the formation of arterial thrombi overlying the site of vessel rupture. Localized exposure of vessel wall procoagulant material, including macrophage/foam cells that express high levels of TF¹¹⁰ and shed TF-positive microparticles,¹¹¹ is the precipitating event in




Figure 3. Recruitment of leukocytes to the growing thrombus. Leukocyte recruitment to the thrombus is influenced by the condition of the endothelium and the shear rate in the vessel. (A) Under low shear with intact endothelium, leukocytes are able to bind adhesive molecules on the endothelial surface such as VWF, selectin family members, and cell adhesion molecules to leukocyte-expressed PSGL-1 or integrin receptors. (B) In arterial thrombosis, leukocyte recruitment to the thrombus is influenced by platelet binding, where glycoprotein receptors/β1 and β3 integrins on activated platelets bind to subendothelial adhesion molecules such as VWF, collagen, laminin, and fibronectin. Leukocytes bind to adhered platelets in a PSGL-1/P-selectin-dependent manner and are further stabilized by additional ligand-receptor interactions. EMMPRIN, extracellular matrix metalloproteinase inducer; JAM-3, junctional adhesion molecule; LFA-1, lymphocyte function-associated antigen 1.

atherothrombosis. Arterial thrombosis occurs under conditions of high shear, whereby circulating platelets bind subendothelial ligands, such as collagen and VWF that facilitate the generation of a platelet-rich thrombus. Activated platelets release cytokines that can modulate leukocyte activation,^{41,112} resulting in the formation of heterotypic leukocyte-platelet aggregates that serve to localize activated leukocytes to the arterial thrombus (Figure 3B). Plasma levels of TF-expressing monocytes and microparticles, leukocyte-platelet aggregates, and NET markers are elevated in conditions that predispose to cardiovascular disease.^{113,114} Histologic analysis of coronary artery and catheter-associated arterial thrombi demonstrated the presence of monocytes, neutrophils, and eosinophils within the thrombi.^{115,116}

Although murine models do not typically display spontaneous atherothrombosis, intravital models of arterial thrombosis address thrombus formation in macrovascular beds in the context of activated or damaged endothelium. Vessel wall TF is unequivocally involved in thrombus initiation in arterial thrombosis,¹¹⁷ however, the role of circulating leukocyte or leukocyte-derived TF regulating arterial thrombus formation is less clear. The inhibition of leukocyte accumulation using an anti-P-selectin antibody in a baboon model of arterial thrombus significantly attenuated fibrin formation and decreased thrombus stability.¹¹⁸ Another study utilizing reciprocal bone marrow transplants between normal and low TF-expressing mice showed no decrease in Rose Bengal-induced carotid artery thrombus formation in healthy mice in the absence of hematopoietic TF.¹⁰¹ However, infusion of microparticles prepared from human monocytes increased fibrin formation in a carotid ligation injury in a TF-dependent manner.¹¹⁹ Because monocyte and microparticle TF activity is generally increased for individuals predisposed to arterial thrombosis, the direct influence of hematopoietic TF on arterial thrombus formation in this context has yet to be clearly elucidated.

The role of neutrophils in the propagation of arterial thrombosis has been characterized in murine carotid artery ferric chloride and ligation models.³⁵ In these studies, elastase/cathepsin G-deficient mice had reduced arterial thrombus formation related to serine-protease degradation of TFPI. Moreover, an anti-H2A-H2B-DNA neutralizing antibody impaired thrombus formation and decreased thrombus stability in normal but not elastase/cathepsin G-deficient mice. This effect may be related to the reduction in co-assembly of elastase, cathepsin G, and TFPI with extracellular nucleosomes,³⁵ although the influence of elastase deficiency on NET formation was not directly evaluated in this model. In animal models, NETs are associated with the lumen overlying the atherosclerotic plaque,¹²⁰ and are found elaborated with TF within the arterial thrombus, suggesting that

NETs may help localize leukocyte-derived TF within the arterial thrombus.¹²¹ Interestingly, the administration of DNase does not attenuate arterial thrombus formation in healthy mice,¹²² although both DNase and/or PAD4 inhibition impair arterial thrombosis in murine models of lupus and atherosclerosis, where animals are predisposed to NET formation.^{123,124}

Leukocytes contribute to microvascular thrombosis and disseminated intravascular coagulation (DIC)

Microvascular thrombosis involves the development of thrombi in the venules, arterioles, and capillaries. Individuals with thrombotic microangiopathies arising from non-infectious etiologies display evidence of elevated NET markers¹²⁵ and impaired DNase function¹²⁶ that may contribute to the acute phase of these disorders. In healthy animals, microvascular thrombosis is evaluated most frequently using chemical or laser-induced endothelial injury models of the cremaster and mesenteric arterioles. In these models, it has been demonstrated that TF delivery to the thrombus is mediated through accumulation of both leukocytes²³ as well as leukocyte-derived microparticles.^{127,128} Adhesion of neutrophils to the activated endothelium occurs immediately, and is mediated through lymphocyte function-associated antigen 1 binding to endothelial ICAM-1, whereas monocyte recruitment occurs 3 to 5 minutes post-injury.²³ Depletion of neutrophils or impaired neutrophil-endothelial cell interactions diminished TF accumulation and thrombus formation, suggesting that TF-positive neutrophils form a focus for thrombus development.²³ Concurrently, TF-expressing microparticles from both vessel wall and leukocyte origin accumulate at the injury in a PSGL-1/P-selectin-dependent manner.^{128,129} Monocyte and microparticle-associated TF may facilitate thrombus propagation, because in the absence of hematopoietic TF, fibrin deposition throughout the thrombus is diminished.¹²⁸

In humans, microvascular thrombosis is most frequently associated with DIC caused by endotoxemia, sepsis, or trauma. Evidence suggests that dysregulated activation of leukocytes is associated with sepsis and/or DIC in humans and animal models. Endotoxin and/or microbes can stimulate the expression of TF on monocytes,^{130,131} formation of leukocyte-derived microparticles,¹³² neutrophil degranulation, and NETosis⁴¹ ex vivo. Patients with sepsis and/or evidence of DIC have evidence of elevated monocyte TF,¹³³ TF-expressing microparticles,¹³⁴ HMGB1,¹³⁵ NET markers,¹³⁶ and leukocyte-platelet aggregates.¹³⁷

In mice, hematopoietic cell TF contributes to the coagulopathy observed models of endotoxemia.¹³⁸ Infusions of extracellular histones in mice mimic the pathophysiology of DIC by inducing thrombocytopenia, the formation of platelet-rich microthrombi,⁸³ and microvascular thrombosis, with concomitant bleeding.⁵⁷ Additionally, elastase/cathepsin G-deficient mice demonstrated decreased fibrin deposition in response to *Escherichia coli* infection, and treatment with an anti-H2A-H2B-DNA antibody diminished fibrin production and microvascular occlusions.³⁵ Similarly, infusion of exogenous HMGB1 can potentiate thrombosis and hemorrhage in kidney and lung microvasculature in a thrombin-induced model of DIC.¹⁰

Resolution of thrombosis by leukocytes

In addition to influencing thrombus induction, leukocytes regulate thrombus persistence and levels of activated or acute phase coagulation factors in the circulation. This includes modulation of fibrinolysis through expression and activation of fibrinolytic mediators. Additionally, leukocytes regulate thrombus resolution and coagulation factor clearance through phagocytosis.

Fibrinolysis

Both monocytes and neutrophils can modulate activity of the fibrinolytic pathway and susceptibility of formed fibrin to fibrinolysis (Figure 1). In vitro fibrinolysis is accelerated in the presence of isolated quiescent neutrophils¹³⁹ and monocytes,¹⁴⁰ and monocyte-derived microparticles¹⁴¹ through several characterized mechanisms. Leukocytes express uPA and its receptor uPAR,¹⁴² and hematopoietic uPA deficiency is associated with attenuated thrombus resolution in vivo.¹⁴³ Leukocytes also express receptors for plasminogen, including enolase, Annexin II, and histone H2B, which localize plasminogen to the leukocyte surface, thereby enhancing activation by tissue-type plasminogen activator (tPA) and/or uPA.¹⁴⁴ Additionally, elastase has been shown to inactivate plasminogen activator inhibitor¹⁴⁵ and activate plasmin in the absence of tPA/uPA.¹⁴⁶

However, under pathological circumstances, activated leukocytes may attenuate endogenous fibrinolytic mechanisms. Lipopolysaccharide-stimulated monocytes inhibit fibrinolysis by increasing activation of thrombin activatable fibrinolysis inhibitor in a TF-dependent manner.¹⁴⁷ NETosis may also influence fibrinolysis and thrombus stability, as the addition of CF-DNA and histones to clotting plasma results in the formation of thicker fibers with greater mechanical stability.¹⁴⁸ In patients with sepsis and elevated CF-DNA levels, clot lysis times are attenuated compared with controls¹⁴⁹; this effect can be replicated by the addition of histone-DNA complex¹⁴⁸ or in the presence of NETing neutrophils.⁵³ The presence of CF-DNA within the clot has been shown to impair plasminogen activation by tPA,⁵³ and the binding of plasmin to fibrin.¹⁵⁰

Phagocytosis

In addition to modulation of fibrinolysis, phagocytic leukocytes play a vital role in regulating the persistence of active coagulation factors and formed thrombi within the vasculature. Plasma levels of coagulation factors strongly influence the propensity for pathological thrombus formation, and regulation of plasma levels of the coagulation factors involves a dynamic balance between biosynthesis, secretion, and clearance. Monocyte and/or macrophages express scavenger receptors, including low-density lipoprotein receptor family (eg, low density lipoprotein receptor-related protein 1), sialic acid-binding

immunoglobulin-type lectin family members, and $\alpha_M\beta_2$ integrin, which regulate the endocytosis of coagulation factors such as VWF and FVIII,^{151,152} activated platelets,¹⁵³ fibrin(ogen),¹⁵⁴ and/or NETs.^{108,155} For example, the depletion of macrophages in vivo is associated with elevated plasma levels of VWF-FVIII,¹⁵¹ a risk-factor for venous and arterial thrombosis. Neutrophils can also contribute to the clearance of activated platelets through interactions mediated by platelet surface P-selectin binding to neutrophil-expressed PSGL-1. This interaction is stabilized by neutrophil-expressed β_2 integrins, and requires phosphatidylserine exposure on the platelet surface to mediate endocytosis of the active platelet.¹⁵⁶

Leukocytes also mediate venous thrombus resolution, a process that in addition to fibrinolysis and phagocytosis involves angiogenesis, fibrosis, and vessel wall remodeling.^{157,158} Circulating leukocytes are recruited to the thrombus by release of proinflammatory cytokines and chemokines, upregulated adhesion molecules on the endothelium,¹⁵⁹ the binding of plasminogen to plasminogen receptors, and the formation of fibrin.¹⁶⁰⁻¹⁶² Leukocyte infiltration is temporally regulated with neutrophils predominating at early stages, and monocytes and macrophages predominating at later stages.¹⁵⁹ In animal models involving neutrophil depletion, IVC ligation in rats was associated with delayed thrombus resolution,¹⁵⁷ although this effect is not observed in mice. However, impaired recruitment of monocytes to the resolving thrombus is associated with increased thrombus size, and decreased neovascularization in murine IVC stasis models.^{158,163}

Although the role of neutrophils in thrombus resolution is not fully characterized, they may contribute to this process by phagocytosing apoptotic cells and by-products of thrombolysis. Monocytes have been shown to regulate thrombus resolution by influencing fibrinolysis, producing growth factors, matrix metalloproteinases,¹⁵⁸ and uPA,¹⁶⁴ which in addition to activating plasminogen mediates cell migration and tissue remodeling.¹⁴³ Importantly, there may be heterogeneous roles for monocyte subtypes in the process of thrombus resolution. Ly6C⁺ monocytes, considered to be proinflammatory, are recruited early to damaged tissue, and have been hypothesized to play a role in phagocytosing apoptotic cells and debris associated with the thrombus. Conversely, Ly6C⁻ resident monocytes patrol the vasculature, are recruited later to sites of vascular damage, and have been hypothesized to contribute to tissue repair.^{165,166}

Active coagulation factors modulate leukocyte activity

Although leukocyte activation can modify blood coagulation, it is well recognized that active coagulation factors and platelets can also regulate the proinflammatory activity of leukocytes (Figure 4). In the context of thrombosis, this relationship of reciprocal activation can serve to recruit leukocytes to the forming thrombus. Both monocytes and macrophages express protease activated receptor-1 (PAR-1), a G-protein coupled receptor that is activated by coagulation factor proteases.¹⁶⁷ Thrombin can induce chemotaxis of both neutrophils¹⁶⁸ and monocytes¹⁶⁹ via PAR-dependent and -independent mechanisms.¹⁷⁰ Conversely, APC inhibits leukocyte chemotaxis through PAR cleavage, and interactions with β_1 and β_3 integrins.^{171,172} Active coagulation factors can also mediate the release of procoagulant materials and inflammatory agents by leukocytes. Thrombin can regulate the production of proinflammatory cytokines including interleukin-6 and tumor necrosis factor- α by monocytes through PAR signaling.¹⁷³ Fibrin and fibrin degradation products can stimulate the release of proinflammatory cytokines from monocytes and macrophages by signaling through TLR4.^{160,161}




Figure 4. Coagulation factors can activate leukocytes. (A) Thrombin and APC cleave PAR-1 expressed on monocytes, and regulate monocyte proinflammatory and procoagulant properties. (B) Coagulation factors and activated platelets interact with neutrophils to regulate neutrophil degranulation, NET release, and phagocytic and chemotactic activities. APC, activated protein C; PAMP, pathogen-associated molecular pattern.

Soluble fibrinogen is a potent inducer of neutrophil degranulation via interactions with $\alpha M\beta 2$ integrin, and can increase phagocytic activity while delaying neutrophil apoptosis.¹⁶² Additionally, activated platelets can interact with neutrophils to induce degranulation¹⁵⁶ and NET formation.⁴¹ Thus, positive feedback between dysregulated procoagulant and proinflammatory pathways within the developing thrombus may enhance the procoagulant phenotype of thrombus-associated leukocytes and exacerbate the development of pathological thrombosis.

Inhibition of leukocyte procoagulant activity as antithrombotic therapy

Current strategies for the clinical management of thrombosis involve the use of prophylactic or on-demand anticoagulant therapies, which are associated with an increased risk for bleeding. Recognition of the contribution of leukocytes to the generation of pathological thrombosis, coupled with limited evidence that leukocytes participate in physiological hemostasis, has resulted in the recent development of rational strategies that specifically target leukocyte-mediated prothrombotic pathways in clinical and preclinical studies. Anti-inflammatory agents such as roflumilast (a phosphodiesterase-4 inhibitor) impair the recruitment of leukocytes to the site of thrombus formation,¹⁷⁴ and are associated with a decreased risk for major cardiovascular events in chronic obstructive pulmonary disease patients.¹⁷⁵ Additionally, statins, which have pleiotropic anticoagulant effects, including reduced expression of TF by monocytes and attenuated release of TF-expressing monocyte-derived microparticles in animal models of hypercholesterolemia,¹¹⁵ are

associated with a decreased incidence of arterial and venous thrombosis in clinical studies.^{176,177}

Preclinical studies that targeted leukocyte recruitment to the thrombus using monoclonal antibodies to P-selectin murine and primate models demonstrated reduced inflammation and/or venous thrombus formation.^{178,179} Other strategies have involved inhibiting the procoagulant agents released by activated leukocytes. Treatment with the PAD inhibitor Cl-amidine is capable of blocking NET release, and attenuates thrombus formation and reduces atherosclerotic lesion areas in murine models.^{123,124} Therapies that decrease the procoagulant activity of histones, including APC,⁵⁷ recombinant soluble TM,¹⁸⁰ non-anticoagulant heparins,¹⁸¹ and neutralizing antibodies,⁵⁷ protect mice from thrombosis and/or histone-mediated death in animal models of acute inflammation. Dismantling NETs with DNase is protective from flow-restricted venous thrombosis,¹⁰³ and arterial thrombosis induced by photochemical injury in a murine model of chronic inflammation.¹²³ Additionally, the utility of DNase in combination with tPA for thrombolysis has demonstrated efficacy in *ex vivo* models.¹⁰² Nucleic acid-binding polymers, which inhibit nucleic acid- and polyphosphate-induced activation of the intrinsic pathway of coagulation have also been shown to prevent thrombosis in mice without increasing the risk of bleeding.¹⁸² Finally, targeting contact pathway activation, such as with monoclonal antibodies to FXII, can reduce thrombus formation in primate models¹⁸³ and may mitigate some of the procoagulant effects associated with high levels of extracellular DNA.

Conclusions

Leukocytes are a dynamic and itinerant component of the innate immune system that mediate a rapid response to procoagulant stimuli. Localized intravascular coagulation involving activated leukocytes likely evolved as an adaptive mechanism to promote the resolution of infection when trauma and epidemics accounted for the majority of human deaths. Improved sanitation, nutrition, and treatment of infection promoted epidemiological transition, associated with an increased life expectancy, and the development of chronic inflammatory diseases such as atherosclerosis. Thus, the activation of leukocyte procoagulant activity in response to sterile inflammation may be maladaptive, and links the coincidence of micro- and macrovascular thrombosis with inflammatory pathologies.

There remain controversies in the literature that pertain to the heterarchical role neutrophils and monocytes play in thrombus formation that may be related to the model of thrombosis used, as well as the pathobiological context in which the thrombus develops. The continued development of physiologically relevant *in vivo* models of thrombosis, and careful assessment of the contribution that leukocytes make to thrombo-inflammatory conditions will provide novel insights into the mechanistic basis of thrombosis. These discoveries may be translated to the clinic through improved identification of individuals at-risk for thrombosis. They may also result in the discovery of novel targets for the development of prophylactic or on-demand anticoagulant treatment, and generate strategies for accelerating thrombus resolution. Although modulation of the axis between inflammation and coagulation must take into consideration the potentially beneficial role that leukocyte activities may have in regulating disease outcome and promotion of thrombus resolution, the development of novel inhibitors of leukocyte-associated

procoagulant activity may ultimately prove effective at reducing the burden of thrombosis worldwide.

Acknowledgments

The authors thank T. Gould and L. Pepler for many helpful discussions.

L.L.S. is supported by a postdoctoral fellowship from the Canadian Institutes for Health Research, and P.C.L. is supported by a grant from the Canadian Institutes for Health Research (MOP-136878).

References

- Kumar DR, Hanlin E, Glurich I, Mazza JJ, Yale SH. Virchow's contribution to the understanding of thrombosis and cellular biology. *Clin Med Res*. 2010;8(3-4):168-172.
- Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. *Nat Rev Immunol*. 2013;13(1):34-45.
- Galligan L, Livingstone W, Volkov Y, et al. Characterization of protein C receptor expression in monocytes. *Br J Haematol*. 2001;115(2):408-414.
- McCachren SS, Diggs J, Weinberg JB, Dittman WA. Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. *Blood*. 1991;78(12):3128-3132.
- McGee MP, Foster S, Wang X. Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation. *J Exp Med*. 1994;179(6):1847-1854.
- Tracy PB, Rohrbach MS, Mann KG. Functional prothrombinase complex assembly on isolated monocytes and lymphocytes. *J Biol Chem*. 1983;258(12):7264-7267.
- Tracy PB, Eide LL, Mann KG. Human prothrombinase complex assembly and function on isolated peripheral blood cell populations. *J Biol Chem*. 1985;260(4):2119-2124.
- Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami-Seren B, Mann KG. Tissue factor activity in whole blood. *Blood*. 2005;105(7):2764-2770.
- Shantsila E, Lip GYH. The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet aggregates and novel mechanisms. *Thromb Haemost*. 2009;102(5):916-924.
- Ito T, Kawahara K, Nakamura T, et al. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. *J Thromb Haemost*. 2007;5(1):109-116.
- Swystun LL, Shin LYY, Beaudin S, Liaw PC. Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes. *J Thromb Haemost*. 2009;7(4):619-626.
- Tollt LJ, Beaudin S, Liaw PC; Canadian Critical Care Translational Biology Group. Activated protein C up-regulates IL-10 and inhibits tissue factor in blood monocytes. *J Immunol*. 2008;181(3):2165-2173.
- Yan SF, Mackman N, Kisiel W, Stern DM, Pinsky DJ. Hypoxia/hypoxemia-induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. *Arterioscler Thromb Vasc Biol*. 1999;19(9):2029-2035.
- Tutwiler V, Madeeva D, Ahn HS, et al. Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia. *Blood*. 2016;127(4):464-472.
- Chen VM, Hogg PJ. Encryption and decryption of tissue factor. *J Thromb Haemost*. 2013;11(suppl 1):277-284.
- Basavaraj MG, Gruber FX, Sovershaev M, et al. The role of TFPI in regulation of TF-induced thrombogenicity on the surface of human monocytes. *Thromb Res*. 2010;126(5):418-425.
- Aleman MM, Gardiner C, Harrison P, Wolberg AS. Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. *J Thromb Haemost*. 2011;9(11):2251-2261.
- Angelillo-Scherrer A. Leukocyte-derived microparticles in vascular homeostasis. *Circ Res*. 2012;110(2):356-369.
- Osterud B, Rao LV, Olsen JO. Induction of tissue factor expression in whole blood: lack of evidence for the presence of tissue factor expression in granulocytes. *Thromb Haemost*. 2000;83(6):861-867.
- Maugeri N, Brambilla M, Camera M, et al. Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. *J Thromb Haemost*. 2006;4(6):1323-1330.
- Nakamura S, Imamura T, Okamoto K. Tissue factor in neutrophils: yes. *J Thromb Haemost*. 2004;2(2):214-217.
- von Brühl M-L, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. *J Exp Med*. 2012;209(4):819-835.
- Darbousset R, Thomas GM, Mezouar S, et al. Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation. *Blood*. 2012;120(10):2133-2143.
- Egorina EM, Sovershaev MA, Olsen JO, Østerud B. Granulocytes do not express but acquire monocyte-derived tissue factor in whole blood: evidence for a direct transfer. *Blood*. 2008;111(3):1208-1216.
- Moosbauer C, Morgenstern E, Cuvelier SL, et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. *Blood*. 2007;109(3):995-1002.
- Cugno M, Marzano AV, Lorini M, Carbonelli V, Tedeschi A. Enhanced tissue factor expression by blood eosinophils from patients with hyper eosinophilia: a possible link with thrombosis. *PLoS One*. 2014;9(11):e111862.
- Sovershaev MA, Lind KF, Devold H, et al. No evidence for the presence of tissue factor in high-purity preparations of immunologically isolated eosinophils. *J Thromb Haemost*. 2008;6(10):1742-1749.
- Pham CTN. Neutrophil serine proteases: specific regulators of inflammation. *Nat Rev Immunol*. 2006;6(7):541-550.
- Meier HL, Heck LW, Schulman ES, MacGlashan DW Jr. Purified human mast cells and basophils release human elastase and cathepsin G by an IgE-mediated mechanism. *Int Arch Allergy Appl Immunol*. 1985;77(1-2):179-183.
- Allen DH, Tracy PB. Human coagulation factor V is activated to the functional cofactor by elastase and cathepsin G expressed at the monocyte surface. *J Biol Chem*. 1995;270(3):1408-1415.
- Gale AJ, Rozenshteyn D. Cathepsin G, a leukocyte protease, activates coagulation factor VIII. *Thromb Haemost*. 2008;99(1):44-51.
- Plescia J, Altieri DC. Activation of Mac-1 (CD11b/CD18)-bound factor X by released cathepsin G defines an alternative pathway of leukocyte initiation of coagulation. *Biochem J*. 1996;319(pt 3):873-879.
- Jochum M, Lander S, Heimburger N, Fritz H. Effect of human granulocytic elastase on isolated human antithrombin III. *Hoppe Seylers Z Physiol Chem*. 1981;362(2):103-112.
- Pratt CW, Tobin RB, Church FC. Interaction of heparin cofactor II with neutrophil elastase and cathepsin G. *J Biol Chem*. 1990;265(11):6092-6097.
- Massberg S, Grah L, von Bruehl M-L, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. *Nat Med*. 2010;16(8):887-896.
- Belaaouaj AA, Li A, Wun T-C, Welgus HG, Shapiro SD. Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. *J Biol Chem*. 2000;275(35):27123-27128.
- Higuchi DA, Wun TC, Likert KM, Broze GJ Jr. The effect of leukocyte elastase on tissue factor pathway inhibitor. *Blood*. 1992;79(7):1712-1719.
- Maugeri N, Campana L, Gavina M, et al. Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. *J Thromb Haemost*. 2014;12(12):2074-2088.
- Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. *J Immunol*. 2012;189(6):2689-2695.
- Tadie J-M, Bae H-B, Jiang S, et al. HMGB1 promotes neutrophil extracellular trap formation through interactions with toll-like receptor 4. *Am J Physiol Lung Cell Mol Physiol*. 2013;304(5):L342-L349.
- Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. *Nat Med*. 2007;13(4):463-469.
- Chow OA, von Köckritz-Blickwede M, Bright AT, et al. Statins enhance formation of phagocyte extracellular traps. *Cell Host Microbe*. 2010;8(5):445-454.

43. von Köckritz-Blickwede M, Goldmann O, Thulin P, et al. Phagocytosis-independent antimicrobial activity of mast cells by means of extracellular trap formation. *Blood*. 2008;111(6):3070-3080.
44. Morshed M, Hlushchuk R, Simon D, et al. NADPH oxidase-independent formation of extracellular DNA traps by basophils. *J Immunol*. 2014;192(11):5314-5323.
45. Yousefi S, Gold JA, Andina N, et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. *Nat Med*. 2008;14(9):949-953.
46. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. *Cancer Res*. 2001;61(4):1659-1665.
47. Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. *Arterioscler Thromb Vasc Biol*. 2012;32(8):1777-1783.
48. Mitroulis I, Kambas K, Chrysanthopoulou A, et al. Neutrophil extracellular trap formation is associated with IL-1 β and autophagy-related signaling in gout. *PLoS One*. 2011;6(12):e29318.
49. Swystun LL, Mukherjee S, Liaw PC. Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. *J Thromb Haemost*. 2011;9(11):2313-2321.
50. Gould TJ, Vu TT, Swystun LL, et al. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. *Arterioscler Thromb Vasc Biol*. 2014;34(9):1977-1984.
51. Barranco-Medina S, Pozzi N, Vogt AD, Di Cera E. Histone H4 promotes prothrombin autoactivation. *J Biol Chem*. 2013;288(50):35749-35757.
52. Longstaff C, Hogwood J, Gray E, et al. Neutralisation of the anti-coagulant effects of heparin by histones in blood plasma and purified systems. *Thromb Haemost*. 2016;115(3):591-599.
53. Varjú I, Longstaff C, Szabó L, et al. DNA, histones and neutrophil extracellular traps exert anti-fibrinolytic effects in a plasma environment. *Thromb Haemost*. 2015;113(6):1289-1298.
54. Ammollo CT, Semeraro F, Xu J, Esmon NL, Esmon CT. Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation. *J Thromb Haemost*. 2011;9(9):1795-1803.
55. Nan B, Lin P, Lumsden AB, Yao Q, Chen C. Effects of TNF- α and curcumin on the expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. *Thromb Res*. 2005;115(5):417-426.
56. Menschikowski M, Hagelgans A, Eisenhofer G, Siegert G. Regulation of endothelial protein C receptor shedding by cytokines is mediated through differential activation of MAP kinase signaling pathways. *Exp Cell Res*. 2009;315(15):2673-2682.
57. Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. *Nat Med*. 2009;15(11):1318-1321.
58. Semeraro F, Ammollo CT, Esmon NL, Esmon CT. Histones induce phosphatidylserine exposure and a procoagulant phenotype in human red blood cells. *J Thromb Haemost*. 2014;12(10):1697-1702.
59. Yang X, Li L, Liu J, Lv B, Chen F. Extracellular histones induce tissue factor expression in vascular endothelial cells via TLR and activation of NF- κ B and AP-1. *Thromb Res*. 2016;137:211-218.
60. Herbert JM, Savi P, Laplace MC, Lale A. IL-4 inhibits LPS-, IL-1 beta- and TNF alpha-induced expression of tissue factor in endothelial cells and monocytes. *FEBS Lett*. 1992;310(1):31-33.
61. Haubitz M, Gerlach M, Kruse HJ, Brunkhorst R. Endothelial tissue factor stimulation by proteinase 3 and elastase. *Clin Exp Immunol*. 2001;126(3):584-588.
62. Michels A, Swystun LL, Albáñez S, et al. Histones induce endothelial von Willebrand factor release and subsequent platelet capture in vitro and in vivo models [abstract]. *Blood*. 2014;123(21). Abstract 2768.
63. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. *Blood*. 2004;104(1):100-106.
64. Hamilton KK, Sims PJ. Changes in cytosolic Ca²⁺ associated with von Willebrand factor release in human endothelial cells exposed to histamine. Study of microcarrier cell monolayers using the fluorescent probe indo-1. *J Clin Invest*. 1987;79(2):600-608.
65. Chen J, Fu X, Wang Y, et al. Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. *Blood*. 2010;115(3):706-712.
66. Yan SLS, Russell J, Granger DN. Platelet activation and platelet-leukocyte aggregation elicited in experimental colitis are mediated by interleukin-6. *Inflamm Bowel Dis*. 2014;20(2):353-362.
67. Christersson C, Johnell M, Siegbahn A. The influence of direct thrombin inhibitors on the formation of platelet-leukocyte aggregates and tissue factor expression. *Thromb Res*. 2010;126(4):e327-e333.
68. Hu H, Varon D, Hjemdahl P, Savion N, Schulman S, Li N. Platelet-leukocyte aggregation under shear stress: differential involvement of selectins and integrins. *Thromb Haemost*. 2003;90(4):679-687.
69. Carestia A, Rivadeneyra L, Romaniuk MA, Fondevila C, Negrotto S, Schattner M. Functional responses and molecular mechanisms involved in histone-mediated platelet activation. *Thromb Haemost*. 2013;110(5):1035-1045.
70. Rinder HM, Bonan JL, Rinder CS, Ault KA, Smith BR. Dynamics of leukocyte-platelet adhesion in whole blood. *Blood*. 1991;78(7):1730-1737.
71. Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. *Blood*. 1996;88(1):146-157.
72. Simon DI, Chen Z, Xu H, et al. Platelet glycoprotein Iba1 is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). *J Exp Med*. 2000;192(2):193-204.
73. Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIb beta3 and stimulated by platelet-activating factor. *J Clin Invest*. 1997;100(8):2085-2093.
74. Lievens D, Zernecke A, Seijkens T, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. *Blood*. 2010;116(20):4317-4327.
75. Schulz C, von Brühl ML, Barocke V, et al. EMMPRIN (CD147/basigin) mediates platelet-monocyte interactions in vivo and augments monocyte recruitment to the vascular wall. *J Thromb Haemost*. 2011;9(5):1007-1019.
76. Diacovo TG, deFougerolles AR, Bainton DF, Springer TA. A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2. *J Clin Invest*. 1994;94(3):1243-1251.
77. Santoso S, Sachs UJH, Kroll H, et al. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. *J Exp Med*. 2002;196(5):679-691.
78. Weyrich AS, Elstad MR, McEver RP, et al. Activated platelets signal chemokine synthesis by human monocytes. *J Clin Invest*. 1996;97(6):1525-1534.
79. Celi A, Pellegrini G, Lorenzet R, et al. P-selectin induces the expression of tissue factor on monocytes. *Proc Natl Acad Sci USA*. 1994;91(19):8767-8771.
80. Renesto P, Chignard M. Enhancement of cathepsin G-induced platelet activation by leukocyte elastase: consequence for the neutrophil-mediated platelet activation. *Blood*. 1993;82(1):139-144.
81. LaRosa CA, Rohrer MJ, Benoit SE, Rodino LJ, Barnard MR, Michelson AD. Human neutrophil cathepsin G is a potent platelet activator. *J Vasc Surg*. 1994;19(2):306-318, discussion 318-319.
82. Seth P, Kumari R, Dikshit M, Srimal RC. Effect of platelet activating factor antagonists in different models of thrombosis. *Thromb Res*. 1994;76(6):503-512.
83. Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. *Blood*. 2011;118(13):3708-3714.
84. Semeraro F, Ammollo CT, Morrissey JH, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. *Blood*. 2011;118(7):1952-1961.
85. Diaz JA, Fuchs TA, Jackson TO, et al; for the Michigan Research Venous Group*. Plasma DNA is elevated in patients with deep vein thrombosis. *J Vasc Surg Venous Lymphat Disord*. 2013;1(4):341-348.
86. van Montfoort ML, Stephan F, Lauw MN, et al. Circulating nucleosomes and neutrophil activation as risk factors for deep vein thrombosis. *Arterioscler Thromb Vasc Biol*. 2013;33(1):147-151.
87. Hölschermann H, Haberbosch W, Terhalle H-M, et al. Increased monocyte tissue factor activity in women following cerebral venous thrombosis. *J Neurol*. 2003;250(5):631-632.
88. Kamikura Y, Wada H, Nobori T, et al. Elevated levels of leukocyte tissue factor mRNA in patients with venous thromboembolism. *Thromb Res*. 2005;116(4):307-312.
89. Himber J, Kling D, Fallon JT, Nemerson Y, Riederer MA. In situ localization of tissue factor in human thrombi. *Blood*. 2002;99(11):4249-4250.
90. Savchenko AS, Martinod K, Seidman MA, et al. Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development. *J Thromb Haemost*. 2014;12(6):860-870.
91. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. *Nat Rev Immunol*. 2011;11(4):264-274.
92. Kaplan ZS, Zarpellon A, Alwis I, et al. Thrombin-dependent intravascular leukocyte trafficking regulated by fibrin and the platelet receptors GPIb and PAR4. *Nat Commun*. 2015;6:7835.
93. Sullivan VV, Hawley AE, Farris DM, et al. Decrease in fibrin content of venous thrombi in selectin-deficient mice. *J Surg Res*. 2003;109(1):1-7.
94. Pendu R, Terraube V, Christophe OD, et al. P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes

- to von Willebrand factor. *Blood*. 2006;108(12):3746-3752.
95. Zarbock A, Ley K, McEver RP, Hidalgo A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. *Blood*. 2011;118(26):6743-6751.
 96. Rao RM, Yang L, Garcia-Cardena G, Luscinskas FW. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. *Circ Res*. 2007;101(3):234-247.
 97. Laurance S, Bertin F-R, Ebrahimi T, et al. Gas6 promotes pro-inflammatory (Ly6Chi) monocyte recruitment in venous thrombosis. *Blood*. 2014;124(21):1533.
 98. Niemetz J, Fani K. Thrombogenic activity of leukocytes. *Blood*. 1973;42(1):47-59.
 99. Himber J, Wohlgensinger C, Roux S, et al. Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. *J Thromb Haemost*. 2003;1(5):889-895.
 100. Zhou J, May L, Liao P, Gross PL, Weitz JI. Inferior vena cava ligation rapidly induces tissue factor expression and venous thrombosis in rats. *Arterioscler Thromb Vasc Biol*. 2009;29(6):863-869.
 101. Day SM, Reeve JL, Pedersen B, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. *Blood*. 2005;105(1):192-198.
 102. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. *Proc Natl Acad Sci USA*. 2010;107(36):15880-15885.
 103. Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. *J Thromb Haemost*. 2012;10(1):136-144.
 104. Heestermans M, Salloum-Asfar S, Salvatori D, et al. Role of platelets, neutrophils, and factor XII in spontaneous venous thrombosis in mice. *Blood*. 2016;127(21):2630-2637.
 105. Martinod K, Demers M, Fuchs TA, et al. Neutrophil histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in mice. *Proc Natl Acad Sci USA*. 2013;110(21):8674-8679.
 106. El-Sayed OM, Dewyer NA, Luke CE, et al. Intact toll-like receptor 9 signaling in neutrophils modulates normal thrombogenesis in mice [published online ahead of print October 16, 2015]. *J Vasc Surg*. doi:10.1016/j.jvs.2015.08.070.
 107. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. *J Cell Biol*. 2010;191(3):677-691.
 108. Kolaczowska E, Jenne CN, Sureward BGJ, et al. Molecular mechanisms of NET formation and degradation revealed by intravital imaging in the liver vasculature. *Nat Commun*. 2015;6:6673.
 109. Martinod K, Witsch T, Farley K, Gallant M, Remold-O'Donnell E, Wagner DD. Neutrophil elastase-deficient mice form neutrophil extracellular traps in an experimental model of deep vein thrombosis. *J Thromb Haemost*. 2016;14(3):551-558.
 110. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. *Proc Natl Acad Sci USA*. 1989;86(8):2839-2843.
 111. Mallat Z, Hugel B, Ohan J, Lesèche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. *Circulation*. 1999;99(3):348-353.
 112. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. *J Cell Biol*. 2001;154(3):485-490.
 113. Owens AP III, Passam FH, Antoniak S, et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. *J Clin Invest*. 2012;122(2):558-568.
 114. Borissoff JI, Joosen IA, Versteilen MO, et al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. *Arterioscler Thromb Vasc Biol*. 2013;33(8):2032-2040.
 115. Ramaola I, Padró T, Peña E, et al. Changes in thrombus composition and profilin-1 release in acute myocardial infarction. *Eur Heart J*. 2015;36(16):965-975.
 116. Riegger J, Byrne RA, Joner M, et al; Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort (PRESTIGE) Investigators. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. *Eur Heart J*. 2016;37(19):1538-1549.
 117. Chi L, Gibson G, Peng Y-W, et al. Characterization of a tissue factor/factor VIIa-dependent model of thrombosis in hypercholesterolemic rabbits. *J Thromb Haemost*. 2004;2(1):85-92.
 118. Palabrica T, Lobb R, Furie BC, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. *Nature*. 1992;359(6398):848-851.
 119. Reinhardt C, von Brühl ML, Manukyan D, et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. *J Clin Invest*. 2008;118(3):1110-1122.
 120. Megens RT, Vijayan S, Lievens D, et al. Presence of luminal neutrophil extracellular traps in atherosclerosis. *Thromb Haemost*. 2012;107(3):597-598.
 121. Stakos DA, Kambas K, Konstantinidis T, et al. Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction. *Eur Heart J*. 2015;36(22):1405-1414.
 122. Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. *Proc Natl Acad Sci USA*. 2007;104(15):6388-6393.
 123. Knight JS, Zhao W, Luo W, et al. Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. *J Clin Invest*. 2013;123(7):2981-2993.
 124. Knight JS, Luo W, O'Dell AA, et al. Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. *Circ Res*. 2014;114(6):947-956.
 125. Fuchs TA, Kremer Hovinga JA, Schatzberg D, Wagner DD, Lämmle B. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. *Blood*. 2012;120(6):1157-1164.
 126. Jiménez-Alcázar M, Napirei M, Panda R, et al. Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies. *J Thromb Haemost*. 2015;13(5):732-742.
 127. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. *J Exp Med*. 2003;197(11):1585-1598.
 128. Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. *Blood*. 2004;104(10):3190-3197.
 129. Gross PL, Furie BC, Merrill-Skoloff G, Chou J, Furie B. Leukocyte-versus microparticle-mediated tissue factor transfer during arteriolar thrombus development. *J Leukoc Biol*. 2005;78(6):1318-1326.
 130. Bancsi MJ, Thompson J, Bertina RM. Stimulation of monocyte tissue factor expression in an in vitro model of bacterial endocarditis. *Infect Immun*. 1994;62(12):5669-5672.
 131. Guha M, O'Connell MA, Pawlinski R, et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocyte cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. *Blood*. 2001;98(5):1429-1439.
 132. Wen B, Combes V, Bonhoure A, Wexler BB, Couraud PO, Grau GE. Endotoxin-induced monocyte microparticles have contrasting effects on endothelial inflammatory responses. *PLoS One*. 2014;9(3):e91597.
 133. Vickers J, Russwurm S, Dohrn B, et al. Monocyte tissue factor (CD142) and Mac-1 (CD11b) are increased in septic patients. *Thromb Haemost*. 1998;79(6):1219-1220.
 134. Hellum M, Øvstebo R, Brusletto BS, Berg JP, Brandtzaeg P, Henriksen CE. Microparticle-associated tissue factor activity correlates with plasma levels of bacterial lipopolysaccharides in meningococcal septic shock. *Thromb Res*. 2014;133(3):507-514.
 135. Sundén-Cullberg J, Norrby-Teglund A, Rouhiainen A, et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. *Crit Care Med*. 2005;33(3):564-573.
 136. Dwivedi DJ, Tolt LJ, Swystun LL, et al; Canadian Critical Care Translational Biology Group. Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. *Crit Care*. 2012;16(4):R151.
 137. Rondina MT, Carlisle M, Fraughton T, et al. Platelet-monocyte aggregate formation and mortality risk in older patients with severe sepsis and septic shock. *J Gerontol A Biol Sci Med Sci*. 2015;70(2):225-231.
 138. Pawlinski R, Wang JG, Owens AP III, et al. Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. *Blood*. 2010;116(5):806-814.
 139. Adams SA, Kelly SL, Kirsch RE, Robson SC, Shephard EG. Role of neutrophil membrane proteases in fibrin degradation. *Blood Coagul Fibrinolysis*. 1995;6(8):693-702.
 140. Grau E, Moroz LA. Fibrinolytic activity of normal human blood monocytes. *Thromb Res*. 1989;53(2):145-162.
 141. Lacroix R, Pawlinski L, Robert S, et al. Leukocyte- and endothelial-derived microparticles: a circulating source for fibrinolysis. *Haematologica*. 2012;97(12):1864-1872.
 142. Kunigal S, Kusch A, Tkachuk N, et al. Monocyte-expressed urokinase inhibits vascular smooth muscle cell growth by activating Stat1. *Blood*. 2003;102(13):4377-4383.
 143. Singh I, Burnand KG, Collins M, et al. Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells. *Circulation*. 2003;107(6):869-875.

144. Das R, Pluskota E, Plow EF. Plasminogen and its receptors as regulators of cardiovascular inflammatory responses. *Trends Cardiovasc Med*. 2010;20(4):120-124.
145. Wu K, Urano T, Ihara H, et al. The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase: the evaluation of its physiologic relevance in fibrinolysis. *Blood*. 1995;86(3):1056-1061.
146. Machovich R, Himer A, Owen WG. Neutrophil proteases in plasminogen activation. *Blood Coagul Fibrinolysis*. 1990;1(3):273-277.
147. Semeraro F, Ammollo CT, Semeraro N, Colucci M. Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins. *Haematologica*. 2009;94(6):819-826.
148. Longstaff C, Varjú I, Sótóny P, et al. Mechanical stability and fibrinolytic resistance of clots containing fibrin, DNA, and histones. *J Biol Chem*. 2013;288(10):6946-6956.
149. Gould TJ, Vu TT, Stafford AR, et al. Cell-free DNA modulates clot structure and impairs fibrinolysis in sepsis. *Arterioscler Thromb Vasc Biol*. 2015;35(12):2544-2553.
150. Komissarov AA, Florova G, Idell S. Effects of extracellular DNA on plasminogen activation and fibrinolysis. *J Biol Chem*. 2011;286(49):41949-41962.
151. van Schooten CJ, Shahbazi S, Groot E, et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. *Blood*. 2008;112(5):1704-1712.
152. Pegon JN, Kurdi M, Casari C, et al. Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. *Haematologica*. 2012;97(12):1855-1863.
153. Hoffmeister KM. The role of lectins and glycans in platelet clearance. *J Thromb Haemost*. 2011;9(suppl 1):35-43.
154. Simon DI, Ezratty AM, Francis SA, Rennke H, Loscalzo J. Fibrin(ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): a nonplasmin fibrinolytic pathway. *Blood*. 1993;82(8):2414-2422.
155. Farrera C, Fadeel B. Macrophage clearance of neutrophil extracellular traps is a silent process. *J Immunol*. 2013;191(5):2647-2656.
156. Maugeri N, Rovere-Querini P, Evangelista V, et al. Neutrophils phagocytose activated platelets in vivo: a phosphatidylserine, P-selectin, and beta2 integrin-dependent cell clearance program. *Blood*. 2009;113(21):5254-5265.
157. Varma MR, Varga AJ, Knipp BS, et al. Neutropenia impairs venous thrombosis resolution in the rat. *J Vasc Surg*. 2003;38(5):1090-1098.
158. Henke PK, Pearce CG, Moaveni DM, et al. Targeted deletion of CCR2 impairs deep vein thrombosis resolution in a mouse model. *J Immunol*. 2006;177(5):3388-3397.
159. Wakefield TW, Strieter RM, Wilke CA, et al. Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. *Arterioscler Thromb Vasc Biol*. 1995;15(2):258-268.
160. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. *J Immunol*. 2001;167(5):2887-2894.
161. Perez RL, Roman J. Fibrin enhances the expression of IL-1 beta by human peripheral blood mononuclear cells. Implications in pulmonary inflammation. *J Immunol*. 1995;154(4):1879-1887.
162. Rubel C, Fernández GC, Dran G, Bompadre MB, Isturiz MA, Palermo MS. Fibrinogen promotes neutrophil activation and delays apoptosis. *J Immunol*. 2001;166(3):2002-2010.
163. Henke PK, Varga A, De S, et al. Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model. *Arterioscler Thromb Vasc Biol*. 2004;24(6):1130-1137.
164. Soo KS, Northeast AD, Happerfield LC, Burnand KG, Bobrow LG. Tissue plasminogen activator production by monocytes in venous thrombolysis. *J Pathol*. 1996;178(2):190-194.
165. Wakefield TW, Myers DD, Henke PK. Mechanisms of venous thrombosis and resolution. *Arterioscler Thromb Vasc Biol*. 2008;28(3):387-391.
166. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. *Nat Rev Immunol*. 2005;5(12):953-964.
167. Howells GL, Macey MG, Chinni C, et al. Proteinase-activated receptor-2: expression by human neutrophils. *J Cell Sci*. 1997;110(pt 7):881-887.
168. Bizios R, Lai L, Fenton JW II, Malik AB. Thrombin-induced chemotaxis and aggregation of neutrophils. *J Cell Physiol*. 1986;128(3):485-490.
169. Bar-Shavit R, Kahn A, Fenton JW II, Wilner GD. Chemotactic response of monocytes to thrombin. *J Cell Biol*. 1983;96(1):282-285.
170. Jenkins AL, Howells GL, Scott E, Le Bonniec BF, Curtis MA, Stone SR. The response to thrombin of human neutrophils: evidence for two novel receptors. *J Cell Sci*. 1995;108(pt 9):3059-3066.
171. Stephenson DA, Tolt LJ, Beaudin S, Liaw PC. Modulation of monocyte function by activated protein C, a natural anticoagulant. *J Immunol*. 2006;177(4):2115-2122.
172. Elphick GF, Sarangi PP, Hyun Y-M, et al. Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. *Blood*. 2009;113(17):4078-4085.
173. Naldini A, Sower L, Bocci V, Meyers B, Carney DH. Thrombin receptor expression and responsiveness of human monocytic cells to thrombin is linked to interferon-induced cellular differentiation. *J Cell Physiol*. 1998;177(1):76-84.
174. Totani L, Amore C, Di Santo A, et al. Roflumilast inhibits leukocyte-platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes. *J Thromb Haemost*. 2016;14(1):191-204.
175. White WB, Cooke GE, Kowey PR, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. *Chest*. 2013;144(3):758-765.
176. Ridker PM, Danielson E, Fonseca FAH, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008;359(21):2195-2207.
177. Glynn RJ, Danielson E, Fonseca FAH, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. *N Engl J Med*. 2009;360(18):1851-1861.
178. Downing LJ, Wakefield TW, Strieter RM, et al. Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis. *J Vasc Surg*. 1997;25(5):816-827, discussion 828.
179. Ramacciotti E, Myers DD Jr, Wroblewski SK, et al. P-selectin/PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis. *Thromb Res*. 2010;125(4):e138-e142.
180. Nakahara M, Ito T, Kawahara K, et al. Recombinant thrombomodulin protects mice against histone-induced lethal thromboembolism. *PLoS One*. 2013;8(9):e75961.
181. Wildhagen KC, Garcia de Frutos P, Reutelingsperger CP, et al. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. *Blood*. 2014;123(7):1098-1101.
182. Jain S, Pitoc GA, Holl EK, et al. Nucleic acid scavengers inhibit thrombosis without increasing bleeding. *Proc Natl Acad Sci USA*. 2012;109(32):12938-12943.
183. Matafonov A, Leung PY, Gailani AE, et al. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. *Blood*. 2014;123(11):1739-1746.